Rolf E. Swenson

This study identifies compound #63 as a potent LZK inhibitor that suppresses tumor growth and enhances EGFR and PI3K pathway blockade in HNSCC and ESCC.

This study develops SMYD3 proteolysis targeting chimeras (PROTACs) for HPV-negative head and neck squamous cell carcinoma, showing effective SMYD3 degradation and reduced oncogenic activity.

A β-galactose-cleavable linker reduces kidney toxicity, enhances tumor targeting and therapeutic efficacy in radiopharmaceutical therapy.

This study identifies LZK as a therapeutic target in HNSCC by showing its regulation of c-MYC and GOF p53, and demonstrates PROTAC-mediated degradation as a potential treatment.

This study develops a small molecule, MC-1, that selectively degrades EP300 over CREBBP, revealing factors governing paralogue-specific degradation and its impact on cancer cell proliferation.

The paper identifies a chemical scaffold targeting hRpn13, revealing a DEUBAD-lacking isoform upregulated in multiple myeloma and demonstrating its potential as a therapeutic target.